New antibody drug shows promise in early cancer trial

NCT ID NCT06929195

First seen Apr 17, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug called TQB2210 in 16 people with advanced solid tumors. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block growth signals. The main goals were to find a safe dose and check for side effects, with a focus on stomach and gastroesophageal junction cancers that overexpress FGFR2b.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

    Changsha, Hunan, 410005, China

  • Shanghai Tenth Hospital, Tongji University

    Shanghai, Shanghai Municipality, 200032, China

  • The Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032, China

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510000, China

Conditions

Explore the condition pages connected to this study.